Table 5 Combination strategies with oncolytic virotherapy in preclinical research works
From: Oncolytic virotherapy: basic principles, recent advances and future directions
Combined therapeutic agents | OVs | Tumor types | Ref. |
|---|---|---|---|
ICIs | |||
PD-1 monoclonal antibody | VG161 | PDAC | |
Anti-PD-L1 | CF-33 | CC | |
PD-1 Blockade | GLV-1h68 | STS | |
Anti-PD-1 antibody | WR.TK-HPGD+ | RCC | |
CTLA-4 blockade | NDV | MEL | |
CTLA-4 antibody | G47Δ | ESCC | |
TIGIT blockade | OVH-aMPD-1 | CC; HCC | |
TIM-3 antibody | vvDD | Lung cancer | |
LAG-3 blockade | VV-scfv-TIGIT | CC | |
Targeted drugs | |||
Ruxolitinib | VSV-IFNβ | NSCLC | |
VSV-Δ51; HSV-1-dICP0 | MEL | ||
TPCA-1 | VSV | Glioma | |
Bortezomib | HSV-1 (34.5ENVE) | OHNC; GBM | |
BKM120 | G47Δ | PC | |
MEKi | T-VEC | MEL | |
A8301 | HSV1617 | RMS | |
IDO inhibitor | JD0G | GBM | |
Rituximab | Reovirus | CLL | |
3TSR | NDV | EOC | |
Axitinib | G47Δ-mIL12 | GBM | |
Sorafenib | JX-594 | HCC | |
Sunitinib | Reovirus | RCC | |
Bevacizumab | hrR3 | STAD | |
G47Δ-mAngio | Glioma | ||
RAMBO | Glioma | ||
HF10 | BRCA | ||
MS-275 | VSV | MEL | |
Trametinib | HSV-1 | Glioma | |
PLX4720 | Reolysin® | MEL | |
Alisertib | MV | Lung cancer | |
Cetuximab | C-REV | CC | |
Olaparib | dl922-947 | ATC | |
ACT therapies | |||
CAR-T and iNKT | rTTVΔTK-IL-21 | Solid tumors | |
CD19 CAR-T | CD19t | Solid tumors | |
CAR-T and TCR-T | MYXV | EOC | |
Dual-specific CAR-T | VSVm-IFNβ or reovirus | MEL; GBM | |
HER2.CAR T cells | CAd-VECPDL1 | PC | |
CD19 CAR-T | AdC68-TMC-tCD19 | solid tumors | |
GD2.CAR-T | Ad5Δ24 | NB | |
TILs | IL-2 armed oncolytic poxvirus | CC | |
CCR5-overexpressing NK cells | CCL5-modified oncolytic VACV | CC | |
EGFR CAR-NK | OV-IL15C | GBM | |
NK T cells | VSVΔM51; reovirus | EOC; BRCA | |
Chemotherapies | |||
Cisplatin | MYXV | EOC | |
Paclitaxel | Rhabdovirus Maraba-MG1 | TNBC | |
Doxorubicin | CGTG-102 | STS | |
Mitomycin-C | CV A21 | BLCA | |
Gemcitabine | dl922-947 | PDAC | |
Temozolomide | NDV | GBM | |
Cyclophosphamide | Ad-VT | BRCA | |
Irinotecan | VV | mCRC | |
